Uncategorized

‘How did they get there first?’ Biotechs forced to learn new patent tricks to protect pipelines

Published

on

For a biotech, your intellectual property is your most prized asset. But a new era of increased global competition means that strong patents, longer stealth periods and even some misdirection can be required to ensure drug developers retain an edge.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version